Correlates of abnormal human immunodeficiency virus cervical cytologic findings were examined among women infected with human immunodeficiency virus and uninfected women. STUDY DESIGN: We performed a cross-sectional analysis of baseline data on demographically similar women with infection or risk factors for it. RESULTS: Among 1050 women without hysterectomy, squamous intraepithelial lesions were more common among women infected with human immunodeficiency virus than among uninfected women (18.8% vs 5.3%; P < .001). In multivariate analysis the association of squamous intraepithelial lesions with human papillomavirus infection was strong; adjusted prevalence ratios were 27 for high-risk, 25 for intermediate-risk, and 10 for lowrisk types (95% confidence intervals, 12-58, 12-54, and 4-25, respectively). Much lower adjusted prevalence ratios were seen for the only other factor significantly associated with squamous intraepithelial lesions, namely, infection with human immunodeficiency virus in conjunction with a reduced CD4 + cell count. Adjusted prevalence ratios were 1.9 for CD4 + cell counts <200 and 1.6 for CD4 + cell counts between 200 and 500 (95% confidence intervals, 1.2-3.0 and 1.0-2.5, respectively). Adjusted attributable fractions calculated for this study population indicated that if both human immunodeficiency virus and human papillomavirus were removed, 47.6% of the observed lesions with atypical squamous cells of uncertain significance and 93.4% of the observed squamous intraepithelial lesions would be prevented. CONCLUSION: Squamous intraepithelial lesions are more common among human immunodeficiency virus-infected women and are associated most commonly with high-and intermediate-risk human papillomavirus types and secondarily with human immunodeficiency virus-associated immune compromise. (Am J Obstet Gynecol 2001;184:584-90.) 
In 1992 the Centers for Disease Control and Prevention added invasive cervical cancer to the list of conditions defining acquired immunodeficiency syndrome (AIDS) in the surveillance case definition for AIDS. 1 Moderate to severe dysplasia was added to the list of category B conditions, those in which the course or management of disease may be complicated by infection with human immunodeficiency virus (HIV). 1 These additions were prompted by research, conducted in the preceding decade, suggesting that an increased rate of cervical dysplasia and an increased prevalence of infection with human papillomavirus (HPV) are found among HIVinfected women. [2] [3] [4] In addition, there have been case reports of advanced cervical disease among HIV-infected women that in some cases progressed rapidly or was recurrent. 5 Despite these reports and the increased risk of dysplasia, most studies have not indicated an increased risk of invasive cancer among HIV-infected women. 3, 6 In this study we examined the prevalence and correlates of abnormal cervical cytologic findings among HIVinfected women and uninfected women with similar risk histories. We included testing for the presence, type, and amount of HPV, the primary etiologic agent of cervical dysplasia. Other factors considered in this analysis included demographics, behavioral risk factors, HIV viral load, and HIV-induced immune suppression as assessed by CD4 + cell counts.
Material and methods
Data presented in this article were collected at the following 4 sites: Johns Hopkins University, Baltimore, Md; Montefiore Medical Center, Bronx, NY; Wayne State University, Detroit, Mich; and Brown University, Providence, RI. Institutional review board approval was obtained from all participating institutions, and all participants gave informed consent before enrollment. The women included in this analysis were enrolled in the HIV Epidemiology Research (HER) Study, described in detail elsewhere. 7 Women were eligible for the study if they showed HIV positivity but had no AIDS-defining conditions (according to the 1987 Centers for Disease Control and Prevention case definition for AIDS 8 ) or if they were not infected with HIV but had a history of sexual or injected-drug-use risk behavior. Study visits were conducted semiannually and included a structured interview detailing demographic information and medical history (including sexual, gynecologic, and obstetric history and drug-use history), a psychosocial evaluation, and a physical examination (including a gynecologic examination with testing for sexually transmitted disease, the collection of specimens for a Papanicolaou test, and HPV testing). At each study visit immunophenotyping was conducted with standard flow-cytometric procedures. 9 Papanicolaou test specimens were collected with a Cytobrush (Medscand, Hollywood, Fla) and an Ayres spatula from women in whom the cervix was present. A single commercial cytologic laboratory (Kyto Diagnostics, LP, New York, NY), where cytopathologists were masked to the participants' HIV serostatus, evaluated all Papanicolaou test results according to a predefined expansion of the Bethesda scoring system for cervical cytologic findings. 10 A senior pathologist who was masked to the participants' HIV serostatus reread all abnormal test results, and 10% of those were read as normal. Study staff were notified of all abnormal cytologic findings within 72 hours of receipt; all women with abnormal cytologic findings were referred for gynecologic follow-up.
Cervical and vaginal secretions and exfoliated cells were collected by cervicovaginal lavage (irrigation of the cervix with 10 mL of phosphate-buffered saline solution, followed by aspiration of the lavage fluid from the posterior vaginal fornix). 11 This lavage fluid was divided into aliquots and frozen at -70°C before testing. Cervicovaginal lavage specimens were tested for HPV by polymerase chain reaction (PCR) in a single laboratory, by means of consensus L1 primers 12, 13 with amplification of the cellular β-globin gene as an internal control. HPV type in the amplified product was identified by hybridization with a generic probe designed to recognize most HPV types and with type-specific probes for HPV types 6, 11, 16, 18, 26, Selected specimens were further tested with a hybridization assay for HPV. Initial specimens were tested by Southern blot analysis. 14 Deoxyribonucleic acid (DNA) was extracted from cells in the cervicovaginal lavage specimen and digested with the restriction enzyme PstI. HPV genomes were detected by Southern blot hybridization with the use of phosphorus 32-labeled HPV types 11, 16, 18, 51, 52, and 53. Sequential low-and high-stringency washes allowed detection and identification of a large spectrum of HPV types on the basis of the sizes of the hybridizing bands. Southern blot interpretations were made by a single experienced observer (Robert Burk); when hybridization data were insufficient to identify a specific type of HPV, the virus was classified as "uncharacterized."
In July 1996, Hybrid Capture analysis was implemented in place of Southern blot analysis to allow comparison with HPV results from other ongoing studies of HIV infection in women. Cervicovaginal lavage specimens were tested with the Hybrid Capture (Digene Corporation, Gaithersburg, Md) assay by means of a single probe mixture containing probes for HPV types 6, 11, 16, 18, HPV 6, 11, 42, 43 , and 44. For purposes of classification, HPV risk categories were assigned according to the results of PCR testing, and women with multiple HPV types were classified by the highest risk type assigned by PCR testing. Specimens that showed negative results by PCR for HPV and positive results for the β-globin control were classified as "no HPV present."
The HIV viral load was determined by an ultrasensitive, second-generation (version 2), branched DNA signal amplification assay (Chiron Corporation, Emeryville, Calif) with a quantification limit of 500 copies/mL. 15 All other laboratory testing was as described by Smith et al 7 according to standard procedures; all data, including laboratory results, presented in this article were obtained from the enrollment study visit.
We used the Pearson χ 2 or Fisher exact test to compare proportions and the Student t test to compare means between groups. We used the Wilcoxon rank-sum test for variables that were not normally distributed. The Cochran-Armitage test for trend was used to assess the significance of trends in prevalence. Univariate (crude) associations are presented in the form of prevalence ratios. Multiple logistic regression was used to identify cor-relates of abnormal cervical cytologic findings. Variables related to the study design were forced into all models. These included type of risk behavior (sexual risk behavior or injected drug use) and HIV status together with CD4 + cell count and the HER Study enrollment sites. In addition to these study design variables, the initial models evaluated the main exposure (HPV risk category), factors suggested to be associated with abnormal cervical cytologic findings in the screening process or in previous studies and those suggested by biologic plausibility. In the screening of variables for inclusion in an initial multivariate model, models were fit containing the study design variables and the variable being evaluated. Variables that exhibited at least a moderate association with the outcome in the presence of these design variables were retained. Variables retained in the final multivariate models included the following: the study design variables, the main exposure variable, variables that attained statistical significance, and confounders whose exclusion meaningfully altered the adjusted odds ratio of any category of the main exposure variable. In arriving at a final model, we used likelihood ratio tests to assess the significance of model terms and examined regression diagnostics. [16] [17] [18] Abnormal cervical cytologic findings were relatively common in the study population. Because this implies that odds ratios derived from logistic regression models cannot necessarily be interpreted as measures of relative risk, adjusted prevalence ratios were calculated for the multivariate models. Both unadjusted and adjusted prevalence ratios were computed in SAS (SAS Institute, Cary, NC) software 19 with the use of PROC GENMOD, with binomial distribution and logarithm link functions. For models with the outcome of atypical squamous cells of uncertain significance (ASCUS), the study population was restricted to women with cytologic diagnoses of ASCUS or normal cytologic findings. Similarly, for models in which the outcome was squamous intraepithelial lesion(s) (SIL), the study population was restricted to women with cytologic diagnoses of SIL or normal cytologic findings. Adjusted attributable fractions and average attributable fractions were computed 20 on the basis of logistic regression models. The study population was not restricted for these models; that is, for ASCUS the outcome was ASCUS versus other cytologic findings, and for SIL the outcome was SIL versus other cytologic findings. Moreover, HPV status and HIV status were represented as dichotomous variables in these models. All analyses were completed in the SAS program.
For HIV status, in addition to the standard adjusted attributable fraction computation, we estimated the reduction in ASCUS (or SIL) cases that would be observed if the prevalence of HPV infection among the HIV-infected women were reduced to that of the women not infected with HIV. We accomplished this estimate by first recomputing the sample sizes for each stratum, assuming that the prevalences of HPV infection were equal for the HIVinfected women and the uninfected women and then multiplying these hypothetic sample sizes by the estimated probability of ASCUS (or SIL) derived from the logistic regression model. These quantities were summed over the strata and compared with the total observed number of cases of ASCUS (or SIL).
Results
Between April 1993 and January 1995 a total of 871 HIV-infected women and 439 uninfected women were enrolled into the HER Study. This analysis was limited to 709 HIV-infected women and 341 uninfected women who had not undergone hysterectomy and who were thus at risk of having cervical SIL. (Participants with a prior hysterectomy or for whom cervical Papanicolaou test results were not available from the enrollment visit [n = 250] were not included.) Women infected with HIV and those not infected were recruited from the same communities and were demographically similar overall; their characteristics were described earlier. 7 The HIV-infected women were less likely to be white, were more likely to report a history of sexually transmitted disease, and were less likely to report >5 recent sex partners or recent "crack" cocaine use.
The Papanicolaou test results of 701 women (66.8%) were read as normal; the presence of ASCUS was detected in 198 of the women (18.9%), and the presence of SIL (low grade or higher, referred to collectively hereafter as SIL) was detected in 151 of the women (14.4%). Of the 151 cases of SIL that were detected, 121 (80%) were low grade and 29 (19%) were high grade; 1 squamous cell carcinoma was detected (0.7%) and was included in the SIL category for analysis.
Using univariate analysis, we found no significant associations between ASCUS or SIL and many of the behavioral and biologic factors previously shown to be associated with these conditions. 3, 21 Neither ASCUS nor SIL was associated with the following: age, age at first sexual intercourse, number of sexual partners (in the past 5 years), history of prostitution, history of sexually transmitted disease, parity, current oral contraceptive use, or history of cigarette smoking. We found no associations with the following potential risk factors: race or ethnicity, socioeconomic status (as measured by income), country of origin, marital status, study site, "crack" cocaine or injection drug use within the past 6 months, trichomoniasis, cervical bleeding on physical examination, or douching within 48 hours before examination. SIL was associated in univariate analysis with clinical bacterial vaginosis 22 (prevalence ratio, 1.4; 95% confidence interval, 1.0-1.9) and with cervical ectopia on examination (prevalence ratio, 1.5; 95% confidence interval, 1.1-2.1), but an association of ASCUS was not found.
The prevalence of SIL was 3.9-fold higher among HIV-infected women (Table I ). The presence of SIL was also highly associated with HIV-induced immune compromise (Table I) ; among HIV-infected women, the prevalence of SIL increased as the CD4 + cell count declined (P trend = .001). The prevalence of SIL among HIV-infected women with CD4 + counts of ≥500/µL did not differ significantly from that among HIV-uninfected women (Table I) . ASCUS was 1.8-fold as common in HIV-infected women, increasing with immunocompromise in these women (P trend = .002) and occurring with equal frequency among HIV-infected women with CD4 + cell counts of ≥500/µL and among uninfected women. The prevalence of SIL increased as the plasma HIV viral load increased (P trend = .001); this trend was not seen for ASCUS (P trend = .22).
The presence of SIL was highly associated with HPV infection (Table I ). The prevalence of SIL was greatly elevated in the presence of high levels of HPV (detected by PCR, Southern blot, or Hybrid Capture), multiple HPV types, or high-risk HPV types (detected by PCR). These conditions were also associated with an increased prevalence of ASCUS but to a lesser extent.
Abnormal cervical cytologic findings were highly associated with HPV infection in both HIV-infected and uninfected women. HPV infection was more common among HIV-infected women (454/701; 65%) than among HIVuninfected women (98/336; 29%; prevalence ratio, 2.2; P < .001). Among HPV-infected women, those who were also infected with HIV were 1.9-fold as likely to have SIL (Table II) . Among women not infected with HPV, the rates of SIL were low in both HIV-infected and uninfected women and did not differ significantly by HIV status (Table  II) . After adjusting for HPV status, we found SIL to be 1.9-fold as common in HIV-infected women; the prevalence of ASCUS in HIV-infected and HIV-uninfected women did not differ significantly after adjustment for HPV status.
In the best-fit multivariate model, the association of SIL with HPV infection was strong (Table III) ; adjusted preva- †Women with multiple HPV types were classified according to the type with the highest risk category.
March 2001 Am J Obstet Gynecol lence ratios were 27 for high-risk, 25 for intermediate-risk, and 10 for low-risk types. HIV-associated immunocompromise (HIV positivity in conjunction with a CD4 + cell count of between 200/µL and 500/µL or <200/µL) was significantly associated with SIL in this population, although with a lower risk estimate than that associated with HPV infection. In this multivariate model, neither bacterial vaginosis nor cervical ectopia remained associated with SIL (data not shown). In multivariate analysis women with high-and intermediate-risk HPV types detected by PCR were found to have 4-fold higher prevalence ratios for ASCUS (Table  III) ; smaller increases were seen for low-risk types and for untypeable HPVs. We found an association of ASCUS with HIV positivity in conjunction with CD4 + counts of <200/µL (Table III) . Study site and reported risk behavior were not significantly associated with either outcome but were retained in both models because they were design variables. No interactions between HIV-associated immunocompromise and HPV infection were seen.
Multivariate models were also run to test for the independent effect of plasma HIV viral load. Similar results were obtained for both ASCUS and SIL. In models containing HIV-associated immunocompromise and HIV viral load, HIV-associated immunocompromise retained statistical significance but HIV viral load did not (data not shown). HIV viral load was also not significantly associated with the prevalence of ASCUS or SIL among women with CD4 + cell counts >500/µL (data not shown).
We next investigated the fraction of ASCUS and SIL attributable to HPV infection and HIV infection. HIV infection increases the risk of ASCUS and SIL in 2 ways. First, HIV infection increases the risk of HPV infection. In this sample of women, 20.1% of the observed ASCUS and 43.5% of the observed SIL would have been prevented if the HPV prevalence among HIV-infected women were reduced to that among women not infected with HIV (Table  IV) . Second, after adjustment for HPV infection, HIV infection moderately increases the risk of ASCUS and significantly increases the risk of SIL. If HIV infection were removed from this sample without a change in the prevalence of HPV infection, 6.4% of the observed ASCUS and 37.7% of the observed SIL would be prevented.
The effect of HPV infection on the risk of both ASCUS and SIL was substantially greater than the effect of HIV infection. Without a change in the distribution of HIV infection, elimination of the effect of detectable HPV would prevent 43.8% of the observed ASCUS and 88.9% Study site and reported risk behavior (sexual risk or history of injection drug use) were included in the final model (as design variables) and were not significantly associated with either outcome.
*Prevalence ratios for ASCUS are calculated among women with ASCUS or normal cytologic findings (n = 874); those for SIL (low grade or higher) are for women with SIL or normal cytologic findings (n = 821).
of the observed SIL (Table IV) . If both HIV infection and HPV infection were removed from the population, 47.6% of the observed ASCUS would be prevented; 42.5% is attributable to HPV infection and 5.1% to the effect of HIV infection on the presence of ASCUS. Similarly, if both HIV and HPV were removed from the population, 93.4% of the observed SIL would be prevented; 72.3% is attributable to HPV infection and 21.1% to the effect of HIV on the presence of SIL.
Comment
A high prevalence of cervical cytologic abnormalities was observed among HIV-infected women in this study; the prevalence of ASCUS and the prevalence of SIL were 1.8-fold and 3.9-fold higher among HIV-infected women than among women not infected with HIV but with similar drug use and sexual risk histories. In multivariate analysis only 2 factors were found to be associated with the presence of SIL: (1) HPV infection, with higher risk for types with greater oncogenic potential, and (2) HIV-associated immunocompromise, especially CD4 + cell counts of <200/µL. In the absence of detectable HPV, no significant increase in SIL was seen among HIV-infected women. Results for ASCUS were similar, although the association with HPV infection was less marked. Reduction in the prevalence of HPV infection among HIV-infected women to that among women not infected with HIV would reduce the prevalence of SIL by 44% and the prevalence of ASCUS by 20%. Conversely, removal of the direct effect of HIV infection without changing HPV prevalence would reduce the prevalence of SIL by almost 40% and that of ASCUS by 6%. In this study population the attributable fraction for SIL associated with HPV infection was very high. Removal of the effect of HPV infection would nearly eliminate the presence of SIL and reduce that of ASCUS by roughly half.
The conclusions drawn from this study are limited by its cross-sectional design and by incomplete records on previous Papanicolaou tests and on the treatment for cervical disease. In addition, because rates of high-grade SIL and carcinoma in situ were very low, we were unable to analyze these more severe outcomes separately. Despite these limitations, the detailed and well-standardized data from this large sample of comparable HIV-infected and uninfected women allow a close examination of the relationship among HIV infection, HIV-associated immunocompromise, HPV infection, and cervical ASCUS and SIL. The analysis presented here may have reduced misclassification bias, because all women with ASCUS were included in a separate category and not mixed with women whose Papanicolaou test results were normal or showed SIL. In addition, HPV misclassification is expected to be low in this study because we used PCR, a highly sensitive technique, for HPV detection and HPV typing with type-specific probes.
The strong associations of SIL with HPV infection and immunocompromise seen in this population have been seen in other populations of HIV-infected and uninfected women. 2, 3, 21, 23 We found no other behavioral or biologic factors to be significantly associated with abnormal cervical cytologic findings. Although many earlier studies have reported an association of SIL with sexual risk behaviors and a variety of other behavioral and demographic factors, more recent studies among women not infected with HIV indicate that these risks are mediated through an increased risk of HPV infection. 21 The attributable fraction for SIL associated with HPV infection reported here was similar to that reported by Schiffman et al 21 for women not infected with HIV; these authors found an attributable fraction for HPV infection of 90% for cervical intraepithelial neoplasia grade 1 and 88% for grades 2 and 3.
When both HIV viral load and HIV-associated immunocompromise were included in the same model, the relationship of HIV viral load to SIL was no longer significant. It is possible that an independent effect of HIV viral load may be seen among women whose HIV infection is more advanced than that of the women included in this analysis, who were free of AIDS-defining conditions. The fact that increased HIV viral load did not independently predict the presence of SIL in our population might suggest that HIV-related increases in SIL prevalence are related more to reduced immune surveillance for HPV or antigens associated with dysplasia and neoplasia than to direct interactions of HIV regulatory proteins with HPV. 24 Perhaps because of small sample size, we did not see an independent effect of high HIV viral load among women with CD4 + cell counts >500/µL, as seen among women with any of several opportunistic infections. Another possibility is that HIV viral load does not affect cervical dysplasia directly; this possibility is supported by the observation that, unlike opportunistic infections and Kaposi's sarcoma, cervical cancer has not decreased after the introduction of highly active antiretroviral therapy. 25 The results of this investigation confirm and extend those of earlier studies. The high prevalence of SIL seen among HIV-infected women in this study reinforces the need for regular Papanicolaou screening in this population, as recommended by the Centers for Disease Control and Prevention. 26 Our findings suggest that increased cervical SIL among HIV-infected women is a result of the following 2 factors: (1) an increased risk of HPV infection itself and (2) the effects of HIV-associated immunocompromise. These results suggest that the HIV-related increases in SIL are mediated both by increasing the risk of HPV infection and by directly altering the likelihood of SIL. Our calculations suggest that in the population described here these effects contribute roughly equally to the increased prevalence of SIL among HIV-infected women. Further biomolecular studies will be required to elucidate the mechanisms by which HIV infection influences HPV acquisition and subsequent development of cervical dysplasia.
